# Effect of Pioglitazone on T2DM Patients With COVID-19

Study · id `cardio:ct-nct04604223` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04604223](<https://clinicaltrials.gov/study/NCT04604223>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04604223

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1506 participants.

## Technical summary

Registry record NCT04604223. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-18 (actual); primary completion 2021-06-29 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1506 participants (planned count; ClinicalTrials.gov record NCT04604223, source copy `cardio:ctgov-nct04604223-2021-03-17`, retrieved 2026-10-26)
- Started: 2021-01-18 (actual) (ClinicalTrials.gov record NCT04604223, source copy `cardio:ctgov-nct04604223-2021-03-17`, retrieved 2026-10-26)
- Primary completion: 2021-06-29 (anticipated) (ClinicalTrials.gov record NCT04604223, source copy `cardio:ctgov-nct04604223-2021-03-17`, retrieved 2026-10-26)
- Completion: 2021-06-29 (anticipated) (ClinicalTrials.gov record NCT04604223, source copy `cardio:ctgov-nct04604223-2021-03-17`, retrieved 2026-10-26)
- Countries: Kuwait; Qatar (ClinicalTrials.gov record NCT04604223, source copy `cardio:ctgov-nct04604223-2021-03-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04604223-2021-03-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Pioglitazone on T2DM Patients With COVID-19
- Acronym: PIOQ8
- Condition: Covid19
- Condition: Type 2 Diabetes
- Intervention (Drug): Pioglitazone 45 mg
- Lead sponsor: Dasman Diabetes Institute
- Lead sponsor class: OTHER
- Collaborator: Ministry of Health, Kuwait
- Collaborator class: OTHER\_GOV
- Collaborator: Texas Diabetes Institute
- Collaborator class: OTHER
- Collaborator: Kuwait University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of pioglitazone on inflammatory response and clinical outcome in T2DM patients with COVID-19: a randomized multicenter double-blind clinical trial (`cardio:pubmed-39308871`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a155ecfd6dd1d9b04fe73e2d2541bc845e04d1ff36407b5986f012bc154e5853
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
